Journal
HERZ
Volume 33, Issue 5, Pages 334-342Publisher
URBAN & VOGEL
DOI: 10.1007/s00059-008-3080-x
Keywords
drug-eluting stents; stent thrombosis; risk reduction strategies; review of data
Categories
Ask authors/readers for more resources
Compared to bare-metal stents (BMS), drug-eluting stents (DES) provide a significant additional reduction in restenosis rates and the need for coronary reinterventions. However, compared to BMS,the risk of very late stent thrombosis (ST) appears to be marginally higher accounting for 0.2-0.6% annual incidence for UP to 3 years and possibly even longer following implantation. Risk reduction strategies include meticulous implantation technique, identification of patients with increased thrombotic risk, exclusion of patients scheduled in short term for major elective surgeries, and extended dual anti-thrombotic treatment for a minimum Of 12 months. Future risk avoidance strategies are briefly reviewed and commented.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available